These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
866 related articles for article (PubMed ID: 6342771)
1. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone. Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771 [TBL] [Abstract][Full Text] [Related]
2. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP. Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976 [TBL] [Abstract][Full Text] [Related]
3. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578 [TBL] [Abstract][Full Text] [Related]
4. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437 [TBL] [Abstract][Full Text] [Related]
5. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group. Glick JH; Barnes JM; Bakemeier RF; Prosnitz LR; Bennett JM; Neiman RS; Costello W; Orlow EL Cancer Treat Rep; 1982 Apr; 66(4):855-70. PubMed ID: 7042087 [TBL] [Abstract][Full Text] [Related]
7. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program. Klimo P; Connors JM Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621 [TBL] [Abstract][Full Text] [Related]
8. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease. Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012 [TBL] [Abstract][Full Text] [Related]
9. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496 [TBL] [Abstract][Full Text] [Related]
10. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. Bonadonna G; Santoro A; Bonfante V; Valagussa P Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323 [TBL] [Abstract][Full Text] [Related]
11. Alternating drug combinations in the treatment of advanced Hodgkin's disease. Santoro A; Bonadonna G; Bonfante V; Valagussa P N Engl J Med; 1982 Apr; 306(13):770-5. PubMed ID: 6174865 [TBL] [Abstract][Full Text] [Related]
12. [The management of Hodgkin's disease with chemotherapy or combined modality treatment]. Tsushita K; Utsumi M; Shimoyama M Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076 [TBL] [Abstract][Full Text] [Related]
13. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related]
14. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754 [TBL] [Abstract][Full Text] [Related]
15. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. Gobbi PG; Pieresca C; Federico M; Di Renzo N; Narni F; Iannitto E; Grignani G; Cavanna L; Avanzini P; Partesotti G J Clin Oncol; 1993 Apr; 11(4):712-9. PubMed ID: 7683044 [TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444 [TBL] [Abstract][Full Text] [Related]
17. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center]. Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222 [TBL] [Abstract][Full Text] [Related]
18. Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. Einhorn LH; Williams SD; Stevens EE; Bond WH; Chenoweth L Cancer; 1983 Apr; 51(8):1348-52. PubMed ID: 6186356 [TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease. Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984 [TBL] [Abstract][Full Text] [Related]
20. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute. Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]